cll spearhead off-the-shelf car-t
blood cancer initi coverag neutral
messag initi coverag cellecti neutral rate cll
cell therapi compani base franc develop allogen off-the-shelf car-t
compani edit genom t-cell healthi donor deriv allogen
car-t subsequ inject patient contrast
autolog approach t-cell must reinject donor patient cll use
talen ex vivo genom edit tool disrupt endogen tcr minim
risk graft-versus-host-diseas gvhd thu enabl allogen cell transfer
cll four univers car-t develop two alreadi clinic
furthest ahead clinic partner servier
 progress last month year howev sever
issu redos adopt price believ allogen approach
spearhead cll may amelior concern allow greater clinic
commerci success fact believ allogen approach could possibl
disrupt field immun oncolog cll ahead term timelin
first compani take allogen car-t clinic may first
receiv approv allogen car-t therapi product
hematolog cancer cll approach creat allogen car-t construct
make use platform technolog known talen transcript activator-lik effector
nucleas genom edit t-cell deriv allogen car-t endogen
tcr knock via talen minim gvhd cll abl edit gene
simultan besid knock cll also use safeti switch
car-t product may offer safeti benefit current cll two program
clinic allogen car-t evalu
two blood cancer aml fact cll provid proof-of-concept
allogen car-t approach cheaper minim gvhd redos
compani expect provid interim data updat program march furthermor
cll develop target ucart preclin
talen amen genom edit zinc finger view believ
genom edit tool might offer distinct advantag
particular beyond hematolog cancer addit random insert
construct genom cll four lead candid oppos surgic
specif insert endogen trac locu may pose technic disadvantag
compet compani highlight cll plan adopt surgic insert
futur ucart compani may also use knockout futur car-t
may benefit cell persist howev seem cll clear strategi
timelin take ucart solid tumor evid use talen
tool allogen solid car-t may sub-optimal provid suffici edit
power incorpor sever genom edit requir solid tumor one
shot electropor admit moment remain unknown mani edit
requir take allogen car-t solid tumor talen may suffic
howev cell viabil may superior electropor talen mrna
compar rnp though remain debat
valuat model includ risk-adjust royalti revenu
probabl market entri aml probabl market entri
bpdcn probabl market entri estim
royalti rate eu servier note
valuat includ follow preclin product candid
b-nhl multipl myeloma dcf yield fair
valuat per share thu initi neutral rate
page analyst certif import disclosur
allogen vs autolog car-t need allogen
autolog patient-specif car-t therapi emerg power
potenti cur therapi cancer particular cancer notion
underscor two approv autolog car-t name novarti
nv kymriah gilead yescarta dlbcl howev
develop autolog car-t technolog wider applic partial
limit patient-specif natur cell therapi time requir
manufactur especi rapidli progress cancer furthermor current
approv car-t product rather expens treatment primarili root
individu manufactur wac kymriah yescarta
respect scalabl could also hinder wider adopt
autolog car-t administr reimburs complex depend
payer segment contractu agreement hospit well tediou
hospit certif could impair autolog car-t adopt revenu
degre lastli probabl importantli clinic manag
safeti issu potenti lethal advers event neurotox
still debat among kol could impair wider adopt well figur
provid overview autolog vs allogen car-t manufactur
figur autolog -t therapi leukapheresi construct viral
transduc patient cell consequ car-t cell express
binder cancer reinject patient modifi
figur allogen -t therapi leukapheresi construct viral
transduc cell healthi donor tcr knock prevent gvhd
prerequisit univers -t furthermor hla knock
surgic insert trac locu pleas note absolut
prerequisit creat allogen cell allogen cell inject
page analyst certif import disclosur
opinion efficaci manufactur univers allogen off-the-
shelf car-t expect improv safeti profil redos potenti
could overcom limit repres major advanc cell therapi
allogen car-t manufactur central facil distribut
multipl clinic site store administr
challeng allogen car-t first foremost univers car-t must
overcom graft-versus-host-diseas gvhd mediat inject car-t
might accomplish autolog car-t still contain endogen
tcr individu patient may attack normal cell anoth individu
caus gvhd therefor allogen car-t need delet impair tcr
signal cll use talen technolog see cut knock
endogen tcr healthi donor subject second possibl challeng
allogen car-t graft reject defin reject infus allogen
car-t recipi patient immun system immun reject
mediat presenc mhc protein gene name hla healthi
donor t-cell alloreact killer t-cell receptor dock
transplant tissu mhc class molecul display donor self-
peptid live donor present self-antigen help maintain self-
toler tcr killer cell recogn match epitop trigger
target cell death cllss four lead ucart carri mhc knock-out
believ put compani disadvantag sever competitor
employ mhc knock-out approach crispr crsp
sangamo asid knock tcr via genom
edit exist sever option deriv allogen car-t first nk
cell repres altern cellular backbon car-t therapi nk cell
requir hla match possess tcr render allogen
priori cell medica privat compani pursu approach second
tcr necessarili knock may suffici
suppress signal celyad cyad control alloreact co-express
inhibitori peptid term cell receptor inhibitori molecul
reduc tcr signal therebi reduc gvhd
mani face allogen car-t
number strategi develop overcom gvhd graft reject
see figur discuss four strategi donor-deriv car-t
repres autolog approach cell still express endogen tcr
hla render allogen use clinic feasibl anoth strategi
use non-alloreact t-cell reduc likelihood gvhd virus-specif
t-cell use allogen transplant treatment viral
infect sinc tcr known specif viral antigen oppos
mix polyclon tcr risk gvhd minim best
knowledg gvhd occur clinic applic non-alloreact
t-cell howev manufactur time cell may long
endogen tcr signal may exhaust car-t cell quickli sinc nk
cell macrophag virtu cell lineag possess tcr
cell potenti use priori allogen cell howev limit data
page analyst certif import disclosur
applic exist regardless altern cell demonstr potent
anti-tumor activ vivo highlight cell medica develop nk
cell approach genom edit repres versatil tool creat
allogen car-t cll use talen disrupt tcr
clinic see chapter
crsp use zfn respect knock
tcr hla locu two compani surgic insert construct
endogen trac locu natur genom site tcr may confer
superior function see chapter ideal univers -t
tcr hla neg includ non-class hla avoid nk cell lysi
nk cell patrol human cell low express level hla recent keyston
symposium cll inde present data target insert
nk cell lysi inhibitor trac simultan
knockout ideal univers cell also includ suicid system control
potenti toxic note cll contain
suicid switch howev best knowledg compani far enough
along abl success develop ideal univers car-t
figur sever strategi use deriv allogen car-t cell
believ genom edit repres feasibl approach
ruella kenderian biodrug
page analyst certif import disclosur
everyth want know genom
edit afraid ask
applic genom edit allogen car-t
last year sever novel genom edit tool develop
optim allow specif effici modif human
nucleas talen meganucleas substanti
predomin last techniqu recent year see figur believ
genom edit pois ideal tool gener allogen car-t
though genom edit
tool equal offer distinct
advantages/disadvantag tabl gilead collabor
sangamo leverag zfn cll neutral
leverag talen crispr crsp buy wholly-
own leverag genom edit
oncolog space collabor juno juno
includ edita
intellia
figur genom edit tool cut dna meganucleas form dimer cut dna
singl domain made dna recognit cleavag domain zfn dimer
like zfn talen cleavag foki mediat rvd recogn nucleotid
use guid rna cut specif dna site delhov qasim
page analyst certif import disclosur
tabl advantag disadvantag differ genom edit tool cellecti
use talen engin allogen car-t close competitor use zfn
sgmo/gild crsp respect note
advantages/disadvantag appli ex vivo edit modifi zych et
page analyst certif import disclosur
techniqueadvantagesdisadvantageslimitationshigh specificityextrem laboriouslow toxicitysingl domain encod two import mn function recognit cleavag recognit larg dna sequencesrecognit sequencehigh costcomplex protein domainspair zfn requir target specif locusrequir screen detect target event animalsoff-target effectstal monom recogn singlenucleotid target sequenceident repeat sequenc within tale arrayclon challengelow cost zfncomplex protein domainshigh specificitylarg size tale molecul difficult deliv cellsmor difficult multiplexingpair talen requir target specif locussimplicityhigh propens off-target effectsefficiencymosaicismlow costpoteni immunogenicityhigh precisionversatilityeasi multiplexingmegatalzfn talencrispr/ target sequenc due necessityof presenc pam sequencesbind effici depend presenceof thymidin nucleotid end sequenceinsuffici varieti recogn sequenceszfn recogn nucleotid sequenceshigh efficiencymor difficult multiplex
tabl compani leverag differ techniqu creat allogen cell differ
genom edit techniqu use knock tcr nk cell effector cell
allogen priori tcr signal suppress co-express
tale citi talen better zfn
talen consid overcom drawback relat zfn see tabl
similarli zfn dna bind fuse foki dna cleav
enzym talen complex consist sequenc protein monom
term tale howev unlik zfn singl tale monom bind one
nucleotid dna target sequenc abil talen recogn singl
nucleotid unquestion advantag zfn recogn
nucleotid triplet decreas design effort talen zfn tale
monom arbitrarili link togeth target desir dna sequenc
howev due expand ident repeat sequenc clone tale
depend presenc thymidin nucleotid target dna end
tale monom taken togeth believ talen amen method
genom edit eas potenti scalabl multiplex howev
suitabl talen allogen car-t
talen suffer sever shortcom includ clone challeng due
repetit natur tale monom gener complex protein
domain furthermor larg size tale molecul render deliveri cell
technic challeng talen pair two protein domain
requir cut dna target site view talen viabl tool
genom edit believ offer sever advantag
talen term simplic eas use low cost importantli easi
multiplex one genom edit sinc guid rna-
base zip code multipl zip code easili co-transfect togeth
protein guid rna small snippet rna nucleotid
length protein pre-incub sever guid rna
deliv ex vivo t-cell genom edit multiplex inde
page analyst certif import disclosur
possibl talen much labori difficult zip code
base two larg talen protein per dna cut hold true even
mrna deliveri talen champion cll cll use pulseagil
technolog transfect talen mrna pulseagil use particularli
effect combin high voltag peak optim creat
transient hole cell membran follow lower voltag puls help
mrna migrat cell pulseagil optim preserv high cell viabil
thu suit large-scal manufactur may advantag
talen specif make dna cut believ
potenti off-target dna break effect case
aris easili detect via guide-seq paper publish biorxiv
charlesworth et al identifi pre-exist adapt immun
protein human preexist humor respons antibodi base
respons convincingli demonstr preexist cell
respons point humor respons pose danger
crsp ex vivo approach allogen car-t human
immun system expos blood circul signific
concern presenc t-cell respons ex vivo approach
mediat gene edit via rnp decreas exposur protein
present mhc protein constitut express usual
degrad rather rapidli within cell believ half-lif long
enough make gene edit though still short enough minim mhc
present simpl workaround would cultur ex vivo edit cell
suffici time interv elimin trace amount inject
human patient recent public schaefer et al natur method
rais concern off-target mutat point howev
view sever flaw experiment design data interpret
paper scientif commun equal critic schaefer et
al believ combin silico guide-seq extens biolog
evalu grna use crsp suffic minim off-target effect
level talen
dna cut confer differ genom edit tool repair two
cellular repair mechan error-pron non-homolog end join nhej
homolog direct repair hdr cell prefer hdr activ
divid homolog repair templat avail wherea nhej occur
mostli non-divid cell leukapheresi cell isol t-cell need
kept happi divid state mean artifici antigen present cell
interleukin cell medium howev longer t-cell kept
state like show exhaust phenotyp therefor
believ genom edit one shot benefici activ allogen
t-cell becom especi import think multiplex
sever genom edit accord cll manag single-puls quintupl
edit possibl use talen howev know compar
dna cut efficaci theoret limit
mani edit perform believ talen may max
page analyst certif import disclosur
single-puls edit due mrna size restrict result
decreas transfect effici talen could use infinit
amount edit use sequenti puls believ single-puls edit
minim exhaust potenti t-cell need kept stimul vitro
cell divis hematolog malign expect number edit
exceed deriv useabl allogen car-t cell howev
multiplex may becom crucial move allogen car-t solid
tumor repres real commerci opportun expect
edit necessari make allogen car-t readi solid tumor solid
tumor may requir knockout also checkpoint
furthermor genome-edit chemokin receptor may becom import
traffick car-t solid tumor taken togeth believ talen
great applic hematolog cancer may limit compar
term solid tumor
optim tune talen specif use non-convent rvd
possibl control fine tune target specif gene edit
domain compos amino acid-long repeat arrang tandem
array individu repeat modul differ two essenti posit
so-cal repeat variabl diresidu rvd contact one
singl nucleotid one strand dna target n-terminu c-terminu
direct line target structur biochem function
studi underlin natur amino acid locat posit
respons specif recognit contact major groov
top dna strand base amino acid posit particip
side stabil repeat unit current tale scaffold turn
robust dna target platform molecular tool today
dna target modul rvd wide implement use
research ni hd ng recent studi start
highlight benefit implement natur rvd howev natur
found rvd explor limit fraction possibl divers
repertoir two key posit natur found rvd present variou
pattern specif four nucleotid cll hypothes explor
combin two key amino acid posit could allow
pinpoint non-convent rvd ncrvd novel altern specif
pattern end cll identifi ncrvd present novel valuabl
specif featur exclus properti addit level specif
control offer altern dna target modul may repres major
advantag allevi off-sit target off-sit target defin sequenc
within genom contain mismatch rel target
sequenc interest consid intend target relat off-sit
sequenc adequ implement ncrvd discrimin
nucleotid present posit mismatch exclus properti
prevent talen activ off-sit sequenc allow process
desir locu juillerat et al natur assum
page analyst certif import disclosur
gener talen develop cll may use
allogen approach significantli improv target specif reduc
off-sit target maintain robust high level gene target
tale platform
figur cll univers car-t develop potenti catalyst
cll develop four ucart differ tumor target see figur
talen use genom edit ut construct randomli
insert via viru oppos surgic insert trac locu
knockout incorpor suicid switch perform
product discuss featur detail
evalu two on-going ph trial interim data present
clinic hold lift ph trial
continu amend protocol ind
anticip file within month compani expect cash runway
thu provid enough fund multipl crucial data readout note
accord manag cll plan use surgic insert
construct trac futur ut develop evidenc
recent data present scientif confer clear strategi solid
tumor miss cll preclin pipelin opinion see chapter
furthermor manag see hla/mhc knockout prerequisit
persist howev assum futur ucart product may equip
modif well evidenc recent poster present
recent keyston symposia cellular therapi februari poster
describ allogen car-t doubl knockout
page analyst certif import disclosur
cll expect present two poster april preclin
data
predict immunotherapi outcom multimod assess minim
residu diseas persist allogen t-cell
pre-clin model acut myeloid leukemia
preclin efficaci allogen t-cell therapi
furthermor servier expect present ph clinic result
ebmt portug march
first-in-human studi allogen t-cell
product high-risk adult patient r/r b-cell preliminari result
studi
ahead allo-sct high risk pediatr patient relapsed/refractori b-
lead product basic
cll har talen technolog exclus licens servier
joint clinic develop program servier see
chapter creat vitro/in vivo clinic valid allogen car-
product poirot et al cancer research order avoid gvhd tcr
tcr receptor gene knock via talen see figur
highli express matur b- t- dendritic-cel
target
campath lemtrada sanofi sni also target gene disrupt
thu surviv host t-cell deplet alemtuzumab
potenti benefit clinic set creat recept environ
long half-lif
alemtuzumab render strong lymphodeplet agent standard
adopt immunotherapi express across lymphocyt
cell could simultan allow host cell deplet engraft
approach becom particularli interest think r/r cll patient
alemtuzumab approv howev note alemtuzumab
four black box warn label must use higher dose cll
potenti exacerb risk profil may hinder wider adopt
potenti promis technolog nevertheless alemtuzumab use clinic
trial lymphodeplet agent doubl knockout
achiev electropor talen mrna t-cell healthi donor
process appar toxic t-cell specif use
talen detect limit deep sequenc potenti
best class off-target rate may due inher specif talen
care select target site minim off-target effect howev
construct surgic insert trac randomli insert viral
potenti
page analyst certif import disclosur
transduct togeth suicid switch gene singl
construct believ random insert may minim full potenti
see chapter may caus genotoxicity/tumorigen
suicid switch may activ rituximab case gvhd
genotoxicity/tumorigen neurotoxicitiy absenc hematopoiet recoveri
without evid residu diseas philip et al blood final
still carri hla/mhc believ may increas possibl graft
reject diminish persist howev accord cll manag
persist may much import model market entri
treatment assign probabl
success commerci indic see figur
figur cellular characterist talen use knock
tcr construct surgic insert trac locu
page analyst certif import disclosur
initi clinic data
first patient dose compassion use ph
trial eu initi june recruit center
 eu far patient treat disclos pediatr
adult patient patient ph trial fail line treatment
includ autolog car-t treatment ph expans underway
univers pennsylvania md anderson summar clinic
efficaci data pediatr adult data compar histor
autolog car-t therapi see tabl seem remark clinic
efficaci pediatr patient good better autolog approach
especi given fact pediatr patient seem significantli
wors even fail prior car-t therapi strikingli efficaci lag
behind adult may result sicker patient howev believ
randomli insert construct trac locu could account
heterogen express result variabl clinic efficaci
shown mice surgic insert trac increas
efficaci eyquem et al natur opinion shortcom
regardless demonstr superior safeti profil adult
well furthermor redos patient adult result
success expans efficaci albeit expans roughli initi
expans believ first success poc redos allogen
car-t get clinic respons may defeat argument need
long-persist least liquid tumor howev persist might key
solid tumor expans blood seen adult patient
though note degre expans differ patient may
caus differ diseas burden heterogen product due
random insert
page analyst certif import disclosur
tabl comparison autolog car-t pediatr
tabl comparison autolog car-t adult
page analyst certif import disclosur
triallymphodeplet patient age diseas statu treatmentdos level car-t cells/kg mrd -cr/criadvers event grade follow-upservi line treatment relaps allo-sctcr nt bm blast condit pt mesmo relaps pt primari refractorycr crpnt rocket pt morpholog diseas pt minim mskcccveri high risk refractori transl nt fhcrcc cfrefractori relaps prior line clin invest rang pt includ patient compassion usec cyclophosphamid cf cyclophosphamid fludarabin cfa cyclophosphamid fludarabin alemtuzumabminim diseas blast morpholog diseas blast complet remiss incomplet hematopoiet recoveri crp complet remiss partial hematopoiet adult patient patient agediseas statu treatmentdos level car-t cells/kg mrd -cr/criadvers event grade follow-upservi kcl cfaall patient inelig fail autolog car-t ycr nt ncicfrelaps ycrjuno schc pt mrd pt yrelaps allo-sctcrnt fhcrcc cf cerelaps eliana cf otheral patient morpholog diseas primari refractori chemorefractori yfirst relaps relaps second line therapi inelig allo-sctcr upenn /- ceall pt mrd chemorefractori second relaps second relpas pedi engl pt morpholog yrelapsecr includ patient compassion usec cyclophosphamid cf cyclophosphamid fludarabin cfa cyclophosphamid fludarabin alemtuzumab ce cyclophosphamid etoposid cevd cyclophosphamid etoposid vincristin dexamethason cdvp cyclophosphamid daunorubicin vincristin prednisoneminim diseas blast morpholog diseas blast complet remiss incomplet hematopoiet pediatr patient biopharmaceut
conclus believ demonstr sever expect
allogen car-t reduc toxic compar efficaci autolog
car-t note patient number low patient popul differ
gener wors howev random insert could
hinder clinic success increas genotoxicity/tumorigen
initi abil redos minim gvhd risk expect servier
develop cancer
gvhd safeti
safeti perspect show rel mild level
one grade three grade one grade pediatr one grade four grade
adult patient one outlier grade cll manag remark
patient extrem high tumor burden tumor bone
marrow time enrol refractori treatment sign
gvhd also mild one adult two pediatr patient show
revers grade skin gvhd seem strike us knock-out
puriti tcr still show gvhd albeit mild signific neurotox
seen one adult two pediatr patient show grade
neurotox recov treatment lymphodeplet
ph studi much stronger autolog trial
combin cyclophosphamid cytarabin addit alemtuzumab
strong lymphodeplet alemtuzumab may respons slow
recoveri blood cell count someth servier
wholli own aml bpdcn
engin t-cell product candid target
antigen locat express leukemia cancer cell acut
myeloid leukemia aml blastic plasmacytoid dendrit cell neoplasm
bpdcn given low/abs express normal hematopoiet stem
cell believ repres viabl target contrast
cll wholli own principl construct like
tcr knock via talen construct
suicid switch randomli insert via viral transduct howev
remain intact alreadi clinic larg scale
gmp manufactur purpos clinic investig start
ind aml bpcdn clear februari new
case aml per year death five-year surviv
relaps rate depend age subtyp ph
trial weill cornel set r/r aml high risk aml bpdcn
rare diseas involv bone marrow skin lymphnod standard care
 sever hundr case diagnos per year bpdcn classifi
myeloid neoplasm acut leukemia classif
orphan drug design potenti shown encourag
page analyst certif import disclosur
